NEW YORK, NY / ACCESSWIRE / March 28, 2017 / Two biotech sector stocks made splashes of a different kind on Monday. Cellect had reported a very successfully performed stem cell transplant on first patient in a Phase I/II, proof of concept study, while Impax made an announcement by adding a critical top management appointment to direct the company into the future.
RDI Initiates Coverage:
Cellect Biotechnology Ltd. https://ub.rdinvesting.com/news/?ticker=APOP
Impax Laboratories Inc. https://ub.rdinvesting.com/news/?ticker=IPXL
Cellect Biotechnology investors had to be elated when they saw the company's stock shoot up 73% to close at $10.90 on Monday. The stock traded between $13.50 and $8.55 during the day, on a total volume of 9,124,841 shares traded. The news behind the stock move was the company's announcement of its first successful stem cell transplant in a first cancer patient of Phase I/II study. The proof of concept ApoGraft01 study, designed to prevent life threatening graft-versus-host-disease (GvHD) disease, will enroll total of 12 patients for the study. Encouraging result in a first patient of this initial study is very hopeful and if Cellect technology turns out to be a viable workaround, Cellect can potentially become a major influence in the stem cell transplant arena and in the treatment of cancer. However, it will take about 5 or 6 years for Cellect to use "ApoGraft" for commercial purpose, provided they pass through all stages successfully. The patient was suffering with blood cancer.
Biotech investors should take note of the statement from Dr. Shai Yarkoni, Cellect's CEO – "After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions." Biotech successes may take a long time but there are huge potential rewards down the line. Though only one patient has successfully responded to the treatment, the Data and Safety Monitoring Board approved two additional patients to receive the ApoGraft(TM) treatment. Once those results are in it will complete first study cohort.
Access RDI's Cellect Biotechnology Research Report at: https://ub.rdinvesting.com/news/?ticker=APOP
Impax Laboratories advanced 37.30% to close at $12.70 on Monday. The stock traded between $13.00 and $10.50 on volume of 12,382,067 shares traded. The surge in stock price of $3.45 came on the news that the company's Board of Directors has appointed Paul M. Bisaro, to be President and CEO of Impax. The decision is clearly a vote of investor confidence in the track record of success of Mr. Bisaro. A middling 56 years old, he has amassed 25 years of experience with generic and branded pharmaceutical companies.
At the beginning of the month, Impax was being considered as one of the stocks in the Biotech and Pharmaceutical industries that would likely benefit from the deregulation approach by the new White House Administration. The company's 4th quarter financials showed weakness, as its revenues decreased 29.7% to $198.4 million as compared to revenues of $282.09 million reported in the 4th quarter of 2015, as products from its generic division faced stiff competition and pricing pressure and resulting in revenue drop from generic division by nearly 39% year-on-year, in the 4th quarter. Investors' optimism on the appointment of Mr. Paul M. Bisaro is by and large justified, given that the significant decline in revenue from Impax's generic division in the last result, the road ahead, however, will not be smooth.
Access RDI's Impax Laboratories Research Report at: https://ub.rdinvesting.com/news/?ticker=IPXL
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.